Novel ADC Promising in Certain Non-Squamous Lung Cancers

(MedPage Today) -- A novel antibody-drug conjugate (ADC) yielded responses in about a fourth of patients with heavily pretreated, MET-positive non-small cell lung cancer (NSCLC), a multicenter phase II trial showed.
The highest objective response...